BenzingaAugust 31, 2026 at 9:45 AM NYLast Month
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
